WTIM
ALXN

Wilmington Trust Investment Management’s Alexion Pharmaceuticals ALXN Stock Holding History

Wilmington Trust Investment Management’s Portfolio ALXN Stock Details ALXN Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2014
Q2 		$766K Sell
4,900
-500
-9% -$79K 0.16% 104
2014
Q1 		$822K Buy
5,400
+1,200
+29% +$191K 0.17% 105
2013
Q4 		$558K Hold
4,200
– – 0.11% 154
2013
Q3 		$488K Hold
4,200
– – 0.1% 166
2013
Q2 		$387K Buy
+4,200
New +$405K 0.08% 218

Other funds holding ALXN

Capital Research Global Investors
Capital Research Global Investors Los Angeles, California $645B AUM 30.41% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
T. Rowe Price Associates
T. Rowe Price Associates Baltimore, Maryland $865B AUM 30.76% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
Jennison Associates
Jennison Associates New York $167B AUM 44.17% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
JP Morgan Chase
JP Morgan Chase New York $1.56T AUM 27.86% 1-Year Est. Return
Sands Capital Management
Sands Capital Management Arlington, Virginia $25.5B AUM 26.46% 1-Year Est. Return
Wells Fargo
Wells Fargo San Francisco, California $530B AUM 22.01% 1-Year Est. Return
BIT
BlackRock Institutional Trust San Francisco, California $675B AUM 16.26% 1-Year Est. Return

Wilmington Trust Investment Management's ALXN Position: Q2 2014 in Review

Wilmington Trust Investment Management reduced its Alexion Pharmaceuticals (ALXN) stake by 9.3% in Q2 2014, selling an estimated $79K and leaving 4,900 shares worth $766K. The position accounts for 0.16% of the portfolio, ranked #104.

Wilmington Trust Investment Management first reported a position in ALXN in Q2 2013 and has held it in 5 quarters since. The position peaked at $822K in Q1 2014. 521 funds tracked by Wall St. Rank hold ALXN as of Q2 2014.

  • Wilmington Trust Investment Management held 4,900 shares of Alexion Pharmaceuticals worth $766K as of Q2 2014.
  • Wilmington Trust Investment Management sold 500 Alexion Pharmaceuticals shares in Q2 2014, an estimated $79K.
  • Alexion Pharmaceuticals made up 0.16% of Wilmington Trust Investment Management's portfolio in Q2 2014, its #104 holding.
  • Wilmington Trust Investment Management first reported a position in Alexion Pharmaceuticals in Q2 2013 and has held it in 5 quarters since.
  • Wilmington Trust Investment Management's Alexion Pharmaceuticals position peaked at $822K in Q1 2014.
  • 521 funds tracked by Wall St. Rank held Alexion Pharmaceuticals as of Q2 2014.

Based on Wilmington Trust Investment Management's 13F filing for Q2 2014, filed 13 Aug 2014.